Abstract
Intravenous infusion of PGF2α, 0.75 μg per kilogram per minute for 3.5 to 6 hours, during the midluteal phase of the normal menstrual cycle, resulted in a transient diminution in circulating progesterone and estradiol levels in four out of seven subjects. This effect did not result in a significant shortening of the menstrual interval or luteal phase. The effect appeared to be directly at the ovarian level since there was no correlation of alterations in steroid values with LH or FSH changes. Because of serious gastrointestinal side effects and only transient effects on luteal function, it does not appear that systemically administered PGF2α can be used as a luteolytic agent during the normal menstrual cycle.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
